Drug Profile
GSK 2838497A
Alternative Names: GSK 2231395A; GSK 2254232A; GSK 2254233A; GSK 2838500A; GSK 2838501A; GSK 2838502A; GSK 2838503A; GSK 2838504A; GSK 2838505A; GSK 2838506A; GSK 2838507A; GSK 2838508A; GSK2838497A; Non-typeable Haemophilus influenzae (NTHi) vaccine - GSK; Non-typeable Haemophilus influenzae/pneumococcal adult vaccine - GSK; NTHi-10-AS01E; NTHi-PneumoLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Haemophilus vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilus infections; Pneumococcal infections
Most Recent Events
- 27 Aug 2019 No development reported - Phase-II for Haemophilus infections (In the elderly, Prevention, In adults) in Sweden, United Kingdom (IM) (NCT02075541)
- 19 Apr 2017 GlaxoSmithKline completes the phase II NTHI 004 trial for Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom and Sweden (NCT02075541)
- 01 Jul 2014 Phase-II clinical trials in Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom (IM)